Metabolic Regulation of Alloimmunity: Inhibition of PKM2 Attenuates T Cell Activation and Prolongs Allograft Survival 2257247
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.409 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Daniel Mendes und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Organ transplantation is a life-saving therapy, but its success is limited by immune rejection and the toxicity of immunosuppressants. Activation of immune cells depends on metabolic reprogramming, particularly a shift from mitochondrial respiration to aerobic glycolysis (Warburg effect). Pyruvate kinase M2 (PKM2), a glycolytic enzyme upregulated during immune activation, links metabolism to pro-inflammatory gene expression. Although implicated in cancer and autoimmunity, the role of PKM2 in transplant rejection remains unclear. We hypothesized that PKM2 supports alloimmune T-cell responses and that its inhibition could mitigate rejection and improve graft outcomes Methods To assess PKM2 expression during rejection, C57BL/6 (B6) mice received heart grafts from syngeneic B6 or fully mismatched BALB/c (B/c) donors. Heart grafts were harvested and analyzed by FACS on postoperative days (POD) 3 and 7. For T cell alloresponse, CD3+ cells (B/c mice) were treated with PKM2 inhibitors (PKM2i) or vehicle and co-cultured with allogeneic BMDCs (B6 mice). To assess graft survival and immune mechanisms in vivo, heart transplant recipients (B/c → B6) were treated with PKM2i or vehicle (2×/week, i.p.) from POD1—28. Recipient’s spleen and heart grafts were harvested on POD14 for ex vivo analyses (FACS+Histology)
Results
PKM2 expression was strongly upregulated in graft-infiltrating immune cells, peaking in T cells by POD7, while syngeneic grafts remained at baseline. Strikingly, PKM2 inhibition significantly extended graft survival and broadly suppressed T-cell alloimmune responses including reduced T-cell infiltration, lower IFN-γ production (in vitro/in vivo), and decreased expression of activation/proliferation markers (CD25, Ki67). These changes were accompanied by clear histologic evidence of reduced immune-mediated tissue injury.
Conclusion
These findings position PKM2 as a central regulator of T-cell—mediated rejection and a promising therapeutic target for metabolic immune modulation in transplantation. Funding Source n/a Topic Categories Transplantation Immunology (TRAN)
Zitieren
APA
Mendes, D., Borges, T., & Riella, L. (2026). Metabolic Regulation of Alloimmunity: Inhibition of PKM2 Attenuates T Cell Activation and Prolongs Allograft Survival 2257247. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.409
Vancouver
Mendes D, Borges T, Riella L. Metabolic Regulation of Alloimmunity: Inhibition of PKM2 Attenuates T Cell Activation and Prolongs Allograft Survival 2257247. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.409
BibTeX
@article{Mendes2026,
author = {Mendes, Daniel and Borges, Thiago and Riella, Leonardo},
title = {Metabolic Regulation of Alloimmunity: Inhibition of PKM2 Attenuates T Cell Activation and Prolongs Allograft Survival 2257247},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.409}
}
EUVIMED